Skip to main content
Erschienen in: Supportive Care in Cancer 9/2012

01.09.2012 | Short Communication

Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition

verfasst von: Milena Perez Mak, Verônica Torres da Costa e Silva, Regina Matsunaga Martin, Antonio Marcondes Lerario, Luis Yu, Paulo Marcelo Gehm Hoff, Gilberto de Castro Junior

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tumor-induced osteomalacia (TIO) is a paraneoplastic bone mineral disturbance related to fibroblast growth factor 23 (FGF23) overproduction by the tumor, usually from mesenchymal origin. Such condition leads to high phosphate renal wasting and, consequently, to cumbersome symptoms as weakness, bone pain, and fractures.

Method

Case report.

Result

We report a case of an advanced castration-refractory prostate cancer patient, which developed severe hypophosphatemia with elevated phosphate excretion fraction. TIO was suspected, and increased levels of FGF23 reinforced such diagnosis. The patient died 4 months after being diagnosed with TIO.

Conclusion

This case suggests that TIO has a dismal prognosis in prostate cancer patients. The clinical oncology community must be aware about such disturbance that can be present in those patients with weakness, bone pain, and hypophosphatemia.
Literatur
1.
Zurück zum Zitat Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef
2.
Zurück zum Zitat Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Canc 18:R53–R77CrossRef Chong WH, Molinolo AA, Chen CC, Collins MT (2011) Tumor-induced osteomalacia. Endocr Relat Canc 18:R53–R77CrossRef
3.
Zurück zum Zitat Cotant CL, Rao PS (2007) Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia. Am J Kidney Dis 50:1033–1036PubMedCrossRef Cotant CL, Rao PS (2007) Elevated fibroblast growth factor 23 in a patient with metastatic prostate cancer and hypophosphatemia. Am J Kidney Dis 50:1033–1036PubMedCrossRef
4.
Zurück zum Zitat Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef
5.
Zurück zum Zitat Wilkins GE, Granleese S, Hegele RG, Holden J, Anderson DW, Bondy GP (1995) Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 80:1628–1634PubMedCrossRef Wilkins GE, Granleese S, Hegele RG, Holden J, Anderson DW, Bondy GP (1995) Oncogenic osteomalacia: evidence for a humoral phosphaturic factor. J Clin Endocrinol Metab 80:1628–1634PubMedCrossRef
6.
Zurück zum Zitat Pelger RC, Lycklama ANGA, Papapoulos SE, Hamdy NA (2005) Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. Bone 36:1–5PubMedCrossRef Pelger RC, Lycklama ANGA, Papapoulos SE, Hamdy NA (2005) Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management. Bone 36:1–5PubMedCrossRef
7.
Zurück zum Zitat Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM, Berenberg JL (2005) Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol 23:3626–3628PubMedCrossRef Auethavekiat P, Roberts JR, Biega TJ, Toney MO, Christensen RS, Belnap CM, Berenberg JL (2005) Case 3. Oncogenic osteomalacia associated with hemangiopericytoma localized by octreotide scan. J Clin Oncol 23:3626–3628PubMedCrossRef
8.
Zurück zum Zitat Hosking DJ, Chamberlain MJ, Shortland-Webb WR (1975) Osteomalacia and carcinoma of prostate with major redistribution of skeletal calcium. Br J Radiol 48:451–456PubMedCrossRef Hosking DJ, Chamberlain MJ, Shortland-Webb WR (1975) Osteomalacia and carcinoma of prostate with major redistribution of skeletal calcium. Br J Radiol 48:451–456PubMedCrossRef
9.
Zurück zum Zitat Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822PubMedCrossRef Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C (2011) Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377:813–822PubMedCrossRef
10.
Zurück zum Zitat Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Canc Inst 96:879–882CrossRef Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Canc Inst 96:879–882CrossRef
Metadaten
Titel
Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition
verfasst von
Milena Perez Mak
Verônica Torres da Costa e Silva
Regina Matsunaga Martin
Antonio Marcondes Lerario
Luis Yu
Paulo Marcelo Gehm Hoff
Gilberto de Castro Junior
Publikationsdatum
01.09.2012
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2012
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1474-z

Weitere Artikel der Ausgabe 9/2012

Supportive Care in Cancer 9/2012 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.